Health
FDA approves new pancreatic cancer drug that could extend patients' lives
Patients receiving the first‑of‑its‑kind oral drug daraxonrasib lived a median of 13.2 months, versus 6.7 months for those treated with c…
Source CBS Health AI Summary Updated 42m ago
Health 
Story intelligence Beta
Confidence Checking
Views New Be the first to read
Brief read ~25 words
AI Summary
Patients receiving the first‑of‑its‑kind oral drug daraxonrasib lived a median of 13.2 months, versus 6.7 months for those treated with chemotherapy, according to study results.
Read full article on CBS NewsAI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Overuse of inhalers found to increase heart attack risk in asthma and COPD patientsContinue reading
- London neurosurgeons perform first successful AI-assisted operation to remove brain tumourContinue reading
- Standard breast cancer classification may overlook important differencesContinue reading
- Stem cells can contribute to new treatments for heart attacks and Parkinson'sContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow